Medigene to participate in investment and scientific conferences
(Thomson Reuters ONE) -
Medigene AG /
Medigene to participate in investment and scientific conferences
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 18 May, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard)
announces its participation in three upcoming investment and scientific
conferences:
* BioEquity Europe - The 16th Collaborative Gathering of Corporate &
Investment Communities for the European Life Science
Date: 19 - 20 May 2015
Location: Vienna, Austria
Company presentation: 19 May 4.40 pm local time
Speaker: Peter Llewellyn-Davies, CFO Medigene AG
.
* Conférence du LICR, Ludwig Center for Cancer Research of the University of
Lausanne
Date: 21 May 2015
Location: Lausanne, Switzerland
Speaker: Dolores J. Schendel, CSO Medigene AG
* ASCO, American Society of Clinical Oncology Annual Meeting 2015
Date: 29 May - 02 June 2015
Location: Chicago, USA
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed to
partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) EndoTAG(®) and Veregen(® )are registered trademarks of Medigene AG.
These trademarks may be owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1921874/688853.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1921874]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 393873
Anzahl Zeichen: 3407
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 119 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene to participate in investment and scientific conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
